FIB-4 ≥1.3 is correlated with increased DKD risk in T2D, but SGLT2i therapy that lowers FIB-4 attenuates this . Diabzen, [S. l.], v. 3, n. 4, p. 120–127, 2025. Disponível em: https://thediabzen.com/index.php/d/article/view/34. Acesso em: 14 apr. 2026.